aTYR PHARMA INC
No financial data available for ATYR.
Company may not file with SEC or CIK is unresolved.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 2026-05-28 | SCHIMMEL PAUL | Director | Purchase | 100.0K | $0.50 | $50K | 779.1K | View | |
| 2026-02-04 | 2026-02-04 | Shukla Sanjay | Director & President and CEO | Sale | 3,745 | $0.98 | $4K | 153.6K | View | |
| 2026-02-04 | 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Sale | 1,558 | $0.98 | $2K | 37.3K | View | |
| 2026-02-04 | 2026-02-04 | DENYES NANCY | General Counsel | Sale | 1,118 | $0.98 | $1K | 33.1K | View | |
| 2025-10-09 | 2025-10-09 | SCHIMMEL PAUL | Director | Purchase | 318.0K | $0.94 | $299K | 1.41M | View |
Informational purposes only, not investment advice.